Dr. Richard DiMarchi: The Evolution of GLP-1 Science | Ep. 10

In this episode of The GLP-1 Podcast Show, I speak with Dr. Richard DiMarchi, Distinguished Professor at Indiana University and a pioneer in peptide therapeutics, about the scientific journey behind GLP-1 therapies, multiagonist drug development, and future obesity treatments. We explore glucagon, GIP, triple agonists, and emerging innovations shaping metabolic medicine. Listen now on all major platforms! "For decades, glucagon was viewed primarily as a hormone that raises blood glucose. Research later revealed that glucagon could also promote weight reduction and improve liver metabolism when balanced appropriately with GLP-1 activity." Meet the guest: Dr. Richard DiMarchi https://www.linkedin.com/in/richard-dimarchi-642a5710/ is a Distinguished Professor at Indiana University and a recognized leader in peptide therapeutics, diabetes research, and obesity medicine. His work contributed to major advances in insulin, glucagon, and multiagonist therapies, while also helping establish several biotechnology companies. Dr. DiMarchi continues to advance innovation in the treatment of metabolic diseases through research and translational science. Listen to Dr. Richard DiMarchi on The GLP-1 Podcast Show, available on all major platforms. What you will learn: (00:00) Highlight (00:55) Introduction (05:07) GLP-1 evolution (08:52) Multiagonist design (15:22) Glucagon controversy (17:18) GIP role (24:08) Future treatments (29:49) Final Questions 𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: https://www.wisenetix.com/glp1 Instagram: https://www.instagram.com/theglp1podcast/ LinkedIn: https://www.linkedin.com/showcase/the-glp-1-podcast-show/